AstraZeneca vaccine safe and effective in new trial data
ASTRAZENECA's COVID-19 vaccine developed with Oxford University was 79% effective in preventing symptomatic illness in a large trial in Chile, Peru and the United States, the company said yesterday, paving the way for it to apply for U.S. approval. The vaccine was also 100% effective against severe or critical disease and hospitalisation, and was safe, the partners said on Monday, releasing results of the late-stage human trial study of more than 32,000 volunteers across all age groups. The data will give credence to the British shot after results from earlier, separate late-stage studies raised questions about the robustness of the…